CNS Connect
A neurodegenerative resource newsletter for providers, to help you stay informed on the rapidly evolving neurodegenerative research landscape.
FDA-cleared tests
Currently approved blood-based biomarkers
Last updated September 2026
| Test | Analyte(s) | FDA status | Intended use | Care setting | Ordering codes |
|---|---|---|---|---|---|
| Lumipulse® G pTau217/β-Amyloid 1-42 Plasma Ratio Fujirebio | pTau217 and Aβ42, reported as a ratio | FDA cleared May 2025 | Aids in assessing amyloid plaque pathology in adults 55 and older with cognitive decline. Used alongside other clinical information, not as a stand-alone test. | Specialty care | Labcorp 50809 Quest 14258 |
| Elecsys® Phospho-Tau (181P) — pTau181 Roche / Eli Lilly | pTau181 | FDA cleared October 2025 | Cleared for initial frontline use to rule out Alzheimer's-related amyloid pathology in adults 55 and older. | Primary care | Labcorp 483745 Quest 13690 |
| PrecivityAD2 C2N Diagnostics | p-tau217 and Aβ42/40 ratio, by mass spectrometry | FDA cleared August 2026 | For adults 40 and older with cognitive symptoms. Returns an amyloid probability score to help determine whether amyloid plaques are present. | Specialty care | C2N Diagnostics 1001 |
| Elecsys® Phospho-Tau (217P) Plasma Roche / Eli Lilly | pTau217 | FDA cleared August 2026 | Aids in identifying amyloid pathology in adults 55 and older, supporting both rule-in and rule-out assessment in routine laboratory workflows. | Primary & specialty care | Labcorp 484390 Quest 13825 |
Resource library
Tools & links to help support your patients.
A growing collection of guides, recorded sessions, and trial information for providers caring for patients with cognitive concerns.
Showing 7 of 7 resources
No resources in this topic yet.
This library is updated as the team publishes new material. Have a resource to suggest? Email us below.
What you’ll receive
Inside every issue.
By signing up for this quarterly newsletter, you’ll receive information on:
- FDA approvals, authorizations, and clearance updates.
- Current and emerging blood-based biomarkers (BBMs).
- News on Alzheimer's disease therapies and treatment pathways.
- Guidance on incorporating cognitive assessments and BBMs into office workflows.
- Resources to assist with early detection of cognitive decline.
- Invitations to CME-accredited webinars, meetings, and educational events.
- Clinical trial opportunities.
Contact
Reach out to the CNS Connect team.
Questions, resource suggestions, or an event you’d like us to cover.